Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian,Tapan Kadia,Courtney DiNardo,Naval Daver,Gautam Borthakur,Elias Jabbour,Guillermo Garcia-Manero,Marina Konopleva,Farhad Ravandi

DOI: https://doi.org/10.1038/s41408-021-00425-3

IF: 9.812

2021-02-01

Blood Cancer Journal

Abstract:Abstract Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

oncology,hematology